Clinical Trial Update: Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial completed evaluating the immune response to Pneumovax 23 in elderly participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease
• Pneumonia

Drugs mentioned

• Pneumovax 23 (Pneumococcal polysaccharide vaccine 23-valent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Streptococcus Pneumoniae Vaccines | Phase 2 | Status: COMPLETED